Responses
Clinical/translational cancer immunotherapy
Original research
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
Compose a Response to This Article
Other responses
No responses have been published for this article.